Wednesday, July 8, 2026

Patent intelligence · US

US 7767677

Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors

granted A61KA61K31/496A61K31/501A61P
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 4
Applicant portfolio 106
Patent details — US 7767677
Jurisdiction
US
Status
granted
Grant date
Aug 3, 2010
Expiration
Jul 29, 2030
Claims
10
CPC classes
A61K, A61K31/496, A61K31/501, A61P
View on Google Patents ↗

Quick answer

US 7767677 (Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Aug 3, 2010. Expires Jul 29, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
10
CPC classes
A61K, A61K31/496, A61K31/501, A61P, A61P1/16, A61P3/00

More from Xenon Pharmaceuticals Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12319657

    Solid state crystalline forms of a selective potassium channel modulator

    Xenon Pharmaceuticals Inc. · Expires May 29, 2045

    granted
  2. US 12178811

    Methods of treating depressive disorders

    Xenon Pharmaceuticals Inc. · Expires Dec 26, 2044

    granted
  3. US 12171759

    Methods and uses for treating anhedonia

    Xenon Pharmaceuticals Inc. · Expires Dec 19, 2044

    granted
  4. US 11957675

    Methods and uses for treating anhedonia

    Xenon Pharmaceuticals Inc. · Expires Apr 11, 2044

    granted
  5. US 11325902

    Benzenesulfonamide compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Expires May 5, 2042

    granted
  6. US 11299490

    Benzenesulfonamide compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Expires Apr 7, 2042

    granted
  7. US 11203572

    Substituted benzamides and methods of use thereof

    Xenon Pharmaceuticals Inc. · Expires Dec 16, 2041

    granted
  8. US 11174268

    Benzenesulfonamide compouds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Expires Nov 11, 2041

    granted

Frequently asked questions

What is US patent 7767677?

US 7767677 (Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted Aug 3, 2010. Expires Jul 29, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7767677?

Xenon Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 106 pharmaceutical patents for this assignee.

When does US 7767677 expire?

Our index shows an expiration date of Jul 29, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.